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Abstract: Genetic testing for common variants in the CYP2C9 and VKORC1 genes may provide useful clinical information to guide dosing patients receiving oral warfarin. Specifically, the CYP2C9*2, CYP2C9*3 and either the VKORC1 1639 G>A or VKORC1 1173C>T polymorphisms can be used to help predict an approximate warfarin maintenance
dose needed for a particular patient. Although clinical uptake and use of this genotyping has been slow, an increasing body of literature provides evidence of the clinical utility of supplementing traditional warfarin dosing algorithms
with a pharmacogenetic approach. The availability of multiple methods for clinical genotyping provides the opportunity for molecular diagnostic laboratories to introduce genotyping assays tailored to their specific needs based on
variables such as testing volumes, staffing, available instrumentation and needed turnaround times. Three assays
(Invader, Verigene and TaqMan) designed to detect three genetic variations associated with warfarin dosing are
evaluated and compared as potential clinical tests to assist in patient care. Identical genotypes were reported by
each assay for all samples tested but the assays were found to differ in turnaround time, approval status by the U.S.
Food and Drug Administration (FDA), requirements for amount of input genomic DNA and other logistical factors that
might make each assay more favorable in different settings.
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Introduction
Warfarin is well known both for being an effective oral anticoagulant and for its difficulties in
dosing due to its narrow therapeutic range and
the wide interindividual variability in dosing between patients. Although factors such as age,
sex, race, and weight can contribute to this inter
-patient variability, dosing algorithms that include genotyping variants in the cytochrome
P450, family 2, subfamily C, polypeptide 9
(CYP2C9) and vitamin K epoxide reductase
complex, subunit 1 (VKORC1) genes may aid in
achieving the optimal warfarin dose [1, 2]. A
number of laboratory developed tests and commercial products for genotyping for warfarin
dose selection have been introduced in recent
years [3]. Clinical practice has been slow to
adopt genotyping in the care of patients being
treated with warfarin due to clinical concerns
over insufficient evidence supporting the clinical
utility of such testing and a paucity of evidence-

based guidelines on how to use genotyping results to optimize a patient’s warfarin dosing.
New genotype-based dosing guidelines in the
warfarin product insert and results from completed and ongoing prospective studies may
result in increased utilization of genotyping to
predict warfarin sensitivity [4].
The specific variants genotyped for predicting
warfarin sensitivity include the single nucleotide
polymorphisms (SNPs) in CYP2C9 and VKORC1
can be performed in the clinical setting to aid in
the dosing of the oral anticoagulant, warfarin.
Both the R and S enantiomer of warfarin competitively inhibits VKORC1 (the S enantiomer
being the most potent) and the S-warfarin is
mainly metabolized by CYP2C9 making these
two genes and their genetic variants key contributors, along with other factors such as age,
weight, race and diet, to the wide variability in
the optimal daily warfarin dose between patients. The CYP2C9 and VKORC1 SNPs that are
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established as being clinically significant for
determining warfarin dosing include CYP2C9*2
(NP_000762.2:p.Arg144Cys,
rs1799853),
CYP2C9*3
(NP_000762.2:p.Ile359Leu,
rs1057910), which yield reduced enzyme activity, and two VKORC1 SNPs in complete linkage
disequilibrium, normally referred to as VKORC1
1173C>T
(rs9934438;
NT_010393.15:
g.22417957G>A) and VKORC1 -1639G>A
(rs9923231; NT_010393.15: g.22420768C>T)
[5]. The VKORC1 SNPs are non-coding and
therefore are thought to affect optimal warfarin
dose by altering VKORC1 expression [6].
Although methods for sequencing the regions of
the CYP2C9 and VKORC1 genes containing the
clinically significant SNPs, such as Sanger sequencing, could potentially be used in the clinical setting, most molecular diagnostic laboratories choose alternate methods for routine genotyping applications due to regulatory and quality
assurance issues as well as financial constraints and a need for rapid turnaround times
[7]. A large number of molecular testing strategies exist for determining the genotype of an
individual at one or more loci [8]. The anticipated need for warfarin sensitivity genotyping
led to numerous commercial and laboratorydeveloped clinical assays for CYP2C9*2,
CYP2C9*3 and either VKORC1 1173C>T or 1639G>A genotyping. Here two commerciallydeveloped assays and one research use only
(RUO)-based in house laboratory-developed warfarin genotyping assay are evaluated for use in
a molecular testing laboratory.
Materials and methods
DNA samples
A total of fifty human genomic DNA samples
isolated from de-identified peripheral blood
specimens were separated into two sets for use
in this study. DNA sample set A consisted of 24
samples isolated using the MagNA Pure Compact (Roche Diagnostics, Indianapolis, IN) and
set B consisted of 26 DNA samples isolated
using the EZ1 BioRobot (QIAGEN Inc, Valencia,
CA). DNA concentration was measured using
spectrophotometry (A260) and appropriate dilutions were made when necessary for the Invader and TaqMan assays.
Genotyping methods
Common SNPs in CYP2C9 and VKORC1 were
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analyzed using three different methodologies:
the Verigene® System (Nanosphere, Inc.,
Northbrook, IL), Invader chemistry (Third Wave
Technologies, Madison, WI; now owned by
Hologic), and TaqMan PCR assays performed on
the 7500 Fast Real-time PCR System (Applied
Biosystems, Carlsbad, CA). Specifically, CYP2C9
was genotyped with respect to the CYP2C9*1
(wild-type), CYP2C9*2 and CYP2C9*3 alleles
and one of two VKORC1 SNPs in strong linkage
disequilibrium by each method. Because of the
strong linkage disequilibrium between the two
VKORC1 variants and to allow for inter-assay
comparisons, when a variant allele was detected at one locus it was assumed that a variant allele was also present at the other locus.
DNA samples in set A were genotyped by all
three methods and samples in set B were only
genotyped using the Invader and TaqMan assays.
Verigene® genotyping
The Verigene® Warfarin Metabolism Nucleic
Acid Test (IVD) (Nanosphere, Inc., Northbrook,
IL) is an in vitro diagnostic (IVD) assay approved
by the FDA for clinical use. Each single-use, selfcontained test cartridge can be run in a random
access format and contains a set of fluidic
chambers with reagents for processing the attached low-density microarray with replicate
features of oligonucleotide probes designed to
hybridize to the specific alleles to identify
CYP2C9*2, CYP2C9*3 and the VKORC1 polymorphism 1173C>T. Genomic DNA samples
were analyzed without any PCR amplification
steps by pipetting 25 µL of genomic DNA
(recommended concentration of 40-400 ng/µL)
into a single test cartridge with 25 µL of sample
buffer. Cartridges were then inserted into a Verigene® Processor until the automated hybridization, detection and wash steps were completed.
After removing the reagent pack from each cartridge, the microarrays were then analyzed in a
Verigene® Analyzer which automatically makes
genotyping calls of wild-type (homozygous), heterozygous or mutant (homozygous) for each of
the polymorphisms [9-11].
Invader ®genotyping
Invader® Warfarin Analyte-Specific Reagents
(ASRs) were used for CYP2C9*2, CYP2C9*3
and VKORC1 -1639G>A genotyping. These reagents were discontinued after the increased
enforcement by the FDA of policies defining and

Am J Transl Res 2010;2(4):441-446

Warfarin genotyping using three different platforms

regulating the use of ASRs in diagnostic laboratories but individual researchers may be able to
develop similar Invader® testing strategies using
custom designed reagents with general purpose
reagents. Each genomic DNA sample (5 µL; 1080 ng/µL) was first subjected to three separate
15-cycle PCRs (one for each SNP) and the resulting DNA was then used in isothermal Invader® reactions containing Invader® probes
and FRET cassettes on a 96-well plate[12].
Signal amplification during each Invader® reaction resulted in increased fluorescent signal for
one or both alleles being interrogated in each
reaction. Fluorescence for each allele was then
measured on a Tecan GENiosFL plate reader
and calls of either heterozygous or homozygous
for one of the two alleles for each SNP were
determined based on the relative fluorescent
signals. Synthetic DNA controls representing
heterozygous samples and “no template” water
blanks were included for each SNP.
TaqMan® genotyping
For each genomic DNA samples three separate
TaqMan® PCR reactions were carried out on a
96-well plate in a 7500 Fast Real-time PCR System using 1 µL of DNA (5-20 ng/µL). Each PCR
contained a pair of oligonucleotide primers and
two TaqMan® probes predesigned to hybridize
specifically to the two alleles for each SNP
(CYP2C9*2, Assay ID: C__25625805_10;
CYP2C9*3, Assay ID: C__27104892_10;
VKORC1 1173C>T, Assay ID: C__30204875
_10) (Applied Biosystems, Carlsbad, CA). After
40 PCR cycles the relative fluorescence values
for each allele were plotted against each other
on an allelic discrimination plot with the 7500
version 2 software to determine CYP2C9*2,
CYP2C9*3 and VKORC1 1173C>T genotypes.
Each run included previously genotyped genomic DNA controls representing each allele
and “no template” water blanks for each of the
three loci tested.
Nomenclature
CYP2C9*1 is reference or wild-type allele and in
this study refers to CYP2C9 alleles other than
*2
(s1799853)
or
*3
(rs1057910)
(www.cypalleles.ki.se/cyp2c9.htm). Due to the
complete linkage disequilibrium between the
1173C>T
(rs9934438)
and
-1639G>A
(rs9923231) SNPs for VKORC1, haplotype designations (A or B) described elsewhere [1] are
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used to simplify comparisons between assays
targeting different VKORC1 loci.
Results
Genotyping of MagNA pure DNA samples
CYP2C9 and VKORC1 genotypes were obtained
by the Verigene®, Invader® and TaqMan® assays
for all 24 genomic DNA samples extracted using
the MagNA Pure Compact System(set A). One of
these samples, however, had to be repeated
with the Verigene® assay due to an initial “no
call” result. 100% concordance in genotype results was observed between the three assays
for all three loci examined. With respect to
CYP2C9, the samples in set A included 16
(66.7%) with a *1/*1 genotype, 4 (16.7%) with
a *1/*2 genotype, 3 (12.5%) with a *1/*3
genotype and a single sample (4%) homozygous
for CYP2C9*2 (*2/*2). No *2/*3 or *3/*3
genotypes were observed. VKORC1 haplotypes
in this set included 3 AA (12.5%), 12 AB (50%)
and 9 BB (37.5%) DNA samples.
Genotyping of EZ1 DNA samples
DNA samples isolated using the EZ1 BioRobot
(set B) were tested using the Invader® and
TaqMan® assays (Table 1). Genotypes were defined for all 26 samples without the need for
any repeat testing. Samples in set B were also
found to have 100% concordance between the
two genotyping methods for all three loci in
CYP2C9 and VKORC1. Only *1/*1, *1/*2 and
*1/*3 genotypes were detected in CYP2C9 in
16 (61.5%), 8 (30.8%) and 2 (7.7%) of the 26
samples, respectively. VKORC1 haplotypes AA,
AB and BB were detected in 2 (7.7%), 16
(61.5%) and 8 (30.8%) of the 26 samples, respectively.
Assay comparisons
Selected features for each assay were evaluated and compared in Table 1. The Verigene®
assay required the most DNA by volume and
concentration (10-80 ng/µL, 25 µL) the largest
volume and total amount while the TaqMan®
assay required much less DNA (5-20 ng/
µL,1uL). Other comparisons were complicated
due to lack of sample batching needed for the
Verigene assay. The approximate turnaround
times (TATs) for the Verigene®, Invader® and
TaqMan® assays of 1.5, 4.0 and 2.0 hours, re-
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Table 1. Comparative Features of the Verigene®, Invader®, and TaqMan® Genotyping Assays.
Invader®
TaqMan®
Verigene®
DNA Requirements
Post DNA Extraction Turnaround Time
Manipulations Needed
Maximum Batch Size
Unique Features

10-80 ng/μL
(25 μL)
1.5 hr

Minimal
No need for batching
Random Access;
No PCR;
Automated Calls;
IVD Status
ASR=Analyte Specific reagent; IVD=in vitro diagnostic

spectively were based on running a single sample with appropriate controls. Additional samples (up to the maximum batch sizes shown)
were found to have very little effect on the turnaround times for the Invader® and TaqMan®
assays but each additional sample run at the
same time using the Verigene® assay added 510 minutes to the turnaround time for the entire
batch. The relative number of manipulations
shown for each assay reflects the need for only
two pipetting steps per sample for the Verigene® assay, three different PCRs per sample/
control for the TaqMan® assay and three PCRs
and three Invader® reactions per sample/
control for the Invader® assay.
Allelic frequencies
The genotypes of all fifty samples, set A and B
combined (Table 2), were used to calculate observed allelic frequencies which were found to
be similar to the expected frequencies for the
Table 2. CYP2C9 Genotypes and VKORC1
Haplotypes identified

10-80 ng/μL
(5 μL)
4 hr

5-20 ng/μL
(1 μL)
2 hr

Many
26
ASR Reagents;
Discontinued

Intermediate
28
No post-PCR
Manipulation

CYP2C9 and VKORC1 SNPs, further confirming
the accuracy of the assays used. The CYP2C9
*2 and *3 allelic frequencies based on these
50 samples were 0.14 and 0.05, respectively.
The combined allelic frequencies for the
VKORC1 haplotypes A and B were 0.38 and
0.62, respectively.
Discussion
The Verigene®, Invader®, and TaqMan® assays
used in this study were all suitable methods for
genotyping the CYP2C9*2, CYP2C9*3 and
VKORC1 1173C>T or -1639G>A SNPs that contribute to patient-to-patient variability in optimal
warfarin dosing as demonstrated in the 100%
concordance observed between assays. Additionally, the allelic frequencies for CYP2C9*2,
CYP2C9*3 and the VKORC1 variant were comparable to previous reports and other public
information
(www.ncbi.nlm.nih.gov/projects/
SNP/) for predominantly caucasian populations,
supporting the accuracy of the genotyping results [2, 5, 8].

Genotype or Haplotype

Number of
samples

CYP2C9

*1/*1
*1/*2
*1/*3
*2/*2

32
12
5
1

Although some CYP2C9 genotypes were underrepresented or not present in this study
(homozygous for CYP2C9 *2 or *3), the reproducibility of results for control samples included
in each run for the Invader® and TaqMan® assays or run previously for the Verigene® assay
(vendor-supplied DNA used during initial performance verification) indicate excellent performance across genotypes for all three assays.

VKORC1

AA
AB
BB

5
28
17

The IVD status of the Verigene® assay may
make it more favorable to many laboratories for
clinical diagnostic use in the United States. De-

Gene
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pending on the specific application or testing
algorithm, the shorter turnaround time (TAT) of
this assay (approximately 90 min after DNA isolation) may also be a influential factor for laboratories performing testing for physicians who
would like to use the genotype information to
guide optimal warfarin dosing for patients beginning warfarin therapy. The Verigene® assay,
which can be performed with only two pipetting
steps and no data analysis on the part of the
user, requires less technical expertise than the
other assays and could be implemented with
little difficulty in clinical laboratories without
extensive experience in molecular techniques.
Although calculated costs per sample can be
much higher for the Verigene® assay, the added
technologist ‘hands-on’ time and dependence
on multiple controls per run for the Invader®
and TaqMan® assay could make the cost of performing the Verigene® assay more reasonable,
especially if single samples or small batches are
run [3, 13].
The current non-availability of commercial reagents for a warfarin genotyping Invader® assay
would make the implementation of clinical warfarin genotyping with Invader® chemistry difficult for most laboratories without experience in
designing this type of assay. Although other
comparisons of warfarin genotyping methodologies using the Verigene® and Invader® assays
exist in the literature [3, 13] this study also
evaluates TaqMan® PCR genotyping assays. In
the research setting or when larger batches are
processed, the TaqMan® assay could be a more
feasible choice for warfarin genotyping, especially in laboratories already equipped with realtime PCR instruments, such as the 7500 instrument, capable of genotyping with TaqMan® PCR
assays.
The debate and uncertainty, since the initial
2007 warfarin relabeling, surrounding the interpretation and use of warfarin genotype in managing patients being treated with this anticoagulant, has resulted in minimal adoption of
routine clinical genotyping for warfarin dosing
guidance. In January 2010, the FDA further
modified the warfarin product inserts to not only
mention the potential effect of CYP2C9 and
VKORC1 polymorphisms on warfarin dosing but
to also include more detailed dosing guidance
for the various genotypes in the form of a table
(www.fda.gov/Safety/MedWatch/Safety Information/ucm201100.htm) (packageinserts.bms.
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com/pi/pi_coumadin.pdf). Whether or not warfarin genotyping becomes a routine clinical
laboratory test, the time and effort invested by
various clinical molecular diagnostic companies
and molecular laboratories into genotyping assays such as those described in this study may
serve to prepare the health care industry for
future genotyping applications within and outside the field of pharmacogenetics.
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